-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
"With Kinnate's lead BRAF inhibitor KIN-2787 entering Phase 1 clinical trials and the next-generation pan-FGFR inhibitor KIN-3248 recently receiving IND clearance from the US FDA, we expect that by building a longevity leadership team, The Greater China market is ready for potential new product development," said Dr.
Mr.
"I am very honored to join Jiujiu Bio and lead the company to solve the unmet clinical treatment needs of cancer patients in Greater China,
The primary goal of Jiujiu Bio is to further promote the research and development of KIN-2787 in the Greater China market